FDA Issues Complete Response Letter for Lantheus' LNTH-2501 PET Diagnostic Kit, Citing Third-Party Manufacturing Issues
核心洞察
The FDA issued a Complete Response Letter for LNTH-2501 (搜索) (Ga 68 edotreotide), a PET diagnostic imaging kit for neuroendocrine tumors (搜索), citing unresolved third-party manufacturing facility conditions.
The CRL did not identify any concerns with Lantheus' submitted data, nor any issues related to the safety or efficacy of LNTH-2501 (搜索).
Lantheus remains confident in the product and is working with its manufacturing partner and the FDA to resolve the facility-related conditions.
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Lantheus Holdings, Inc. (搜索) regarding its New Drug Application (NDA) for LNTH-2501 (搜索) (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor (搜索)-positive (SSTR+) neuroendocrine tumors (搜索) (NETs). The CRL, announced by the company on June 26, 2026, means the agency cannot approve the NDA by the Prescription Drug User Fee Act (PDUFA) action date of June 29, 2026.
The FDA's decision stems entirely from unresolved third-party facility manufacturing-related conditions. The third-party facility is responsible for drug product manufacturing, and satisfactory resolution of the unresolved facility inspection-related conditions is required before the LNTH-2501 (搜索) NDA may be approved.
Notably, the CRL did not identify any concerns regarding the data submitted by Lantheus in support of the application, nor did it identify any issues related to the safety or efficacy of LNTH-2501 (搜索).
"We remain confident in LNTH-2501 (搜索) and are committed to bringing this imaging agent to NETs patients and healthcare providers as soon as possible," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus. "The feedback received from the FDA relates solely to our third-party manufacturer, and not to the clinical performance of the product. We are working closely with our partner and the Agency to address these facility manufacturing-related conditions and advance the program."
About LNTH-2501 (搜索)
LNTH-2501 (搜索) (Kit for Preparation of Ga 68 edotreotide Injection) is an investigational radioactive diagnostic kit indicated for use with positron emission tomography (PET) for localization of somatostatin receptor (搜索)-positive neuroendocrine tumors (搜索) in both adult and pediatric patients. The product is supplied as a 2-vial kit to radiopharmacies, allowing for direct preparation of Ga 68 edotreotide injection using the eluate of Gallium from an on-site generator at the radiopharmacy.
LNTH-2501 (搜索) is not currently approved by the FDA and is not yet available for sale in the United States.
Company Background
Lantheus is a leading radiopharmaceutical-focused company headquartered in Massachusetts, with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom. The company has been providing radiopharmaceutical solutions for 70 years, with a mission to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes.